Novel Sirolimus-Coated Balloon Catheter: In Vivo Evaluation in a Porcine Coronary Model.
Yvonne Patricia Clever, Daniel Peters, Jorge Calisse...
https://pubmed.ncbi.nlm.nih.gov/27069105/Actively Recruiting
Led by Concept Medical Inc. · Updated on 2026-01-02
368
Participants Needed
29
Research Sites
217 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of a sirolimus drug coated balloon compared to standard balloon angioplasty for treating below the knee arterial disease. This pivotal, prospective, randomized, two-arm, placebo-controlled trial will be conducted at about 80 sites worldwide, including the USA, Europe, Australia, and Asia. The study addresses the high burden of limb loss caused by peripheral arterial disease and explores sirolimus as an alternative to paclitaxel for drug coated balloons below the knee. Participants will be randomly assigned in equal groups to receive either the MagicTouch PTA sirolimus coated balloon catheter plus standard balloon angioplasty or a placebo balloon angioplasty plus standard balloon angioplasty. All patients first receive pre-dilation with a standard balloon angioplasty. The sirolimus coated balloon is used as an additional treatment after successful lesion preparation. The trial is single-blind and multicenter, aiming to compare outcomes between these two treated groups. During the study, participants will undergo assessments including angiographic evaluations and monitoring of limb health. The primary outcome is primary patency at 12 months, defined by freedom from vessel occlusion, restenosis, target lesion revascularization, and major amputation. Safety will also be evaluated at 6 months and 30 days with composite endpoints. Secondary outcomes include various safety and efficacy measurements up to 60 months. This comprehensive follow-up will help assess long-term treatment effects and participant safety throughout the study period.
CONDITIONS
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
F
Farhana Siddique
D
Dario Gattuso
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Concept Medical Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Sirolimus‑coated balloon | Placebo balloon | Standard balloon angioplasty |
|---|---|---|---|
| What this option is | A sirolimus‑coated angioplasty balloon used after standard balloon angioplasty | A placebo balloon angioplasty used after standard balloon angioplasty | Conventional uncoated balloon angioplasty (PTA) |
| Role in the trial | Investigational device arm | Control arm with placebo balloon | Non‑trial current standard care comparator |
| Why it is used | To reduce restenosis and improve vessel patency compared with placebo after angioplasty | To serve as control and assess effect of sirolimus coating | Common revascularization technique in BTK peripheral artery disease |
| How it is performed | Used after standard balloon angioplasty during the same procedure | Used after standard balloon angioplasty as a placebo procedure | Performed as standard uncoated balloon dilation during angioplasty |
| Existing evidence | Evidence limited to pilot or early studies; no large definitive outcomes yet | Control arm; no efficacy claim | Established effects on revascularization outcomes; meta‑analyses show similar limb salvage and survival compared with DCBs in some analyses |
| Important limitations | Evidence currently limited to early or pilot studies; long‑term limb outcomes not yet shown | Placebo design limits efficacy interpretation relative to current practice | Higher rates of restenosis and target lesion revascularization have been reported with standard PTA versus DCBs in some studies |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day 0 or single treatment procedure
Participants undergo angioplasty treatment of the lower limb arteries. This involves pre-dilatation with a standard balloon angioplasty followed by randomization to either a sirolimus drug coated balloon or a placebo balloon angioplasty in addition to the standard procedure.
1 treatment visit (in-person)
Duration - Up to 60 months
Participants are monitored for safety and effectiveness outcomes following the angioplasty treatment over several years.
Visits at 1, 3, 6, 12, 24, 36, 48 and 60 months
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yvonne Patricia Clever, Daniel Peters, Jorge Calisse...
https://pubmed.ncbi.nlm.nih.gov/27069105/Sabine Steiner, Andrea Willfort-Ehringer, Horst Sievert...
https://pubmed.ncbi.nlm.nih.gov/29730375/Kenneth Rosenfield, Michael R Jaff, Christopher J White...
https://pubmed.ncbi.nlm.nih.gov/26106946/Daniele Giacoppo, Salvatore Cassese, Yukinori Harada...
https://pubmed.ncbi.nlm.nih.gov/27539695/Thomas Zeller, Iris Baumgartner, Dierk Scheinert...
https://pubmed.ncbi.nlm.nih.gov/25301459/Stefan Verheye, Mathias Vrolix, Indulis Kumsars...
https://pubmed.ncbi.nlm.nih.gov/28964764/Ankur Patel, Farah G Irani, Uei Pua...
https://pubmed.ncbi.nlm.nih.gov/34227886/Jihad A Mustapha, Marianne Brodmann, Patrick J Geraghty...
https://pubmed.ncbi.nlm.nih.gov/31368893/Edward Choke, Tjun Yip Tang, Eilane Peh...
https://pubmed.ncbi.nlm.nih.gov/34911383/Concept Medical Inc.
Lead Sponsor